Modulation of dendritic cell differentiation and maturation by decoy receptor 3

被引：102

作者：

Hsu, TL

Chang, YC

Chen, SJ

Liu, YJ

Chiu, AW

Chio, CC

Chen, LP

Hsieh, SL ^{[1
]}

机构：

[1] Natl Yang Ming Univ, Dept Microbiol & Immunol, Taipei 112, Taiwan

[2] Natl Yang Ming Univ, Immunol Res Ctr, Taipei 112, Taiwan

[3] Chi Mei Foundat Hosp, Tainan, Taiwan

[4] Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA

[5] DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA

来源：

JOURNAL OF IMMUNOLOGY | 2002年 / 168卷 / 10期

关键词：

D O I：

10.4049/jimmunol.168.10.4846

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Decoy receptor 3 (DcR3), a soluble receptor belonging to the TNFR superfamily, is a receptor for both Fas ligand (FasL) and LIGHT. It has been demonstrated that DcR3 is up-regulated in lung and colon cancers, thus promoting tumor growth by neutralizing the cytotoxic effects of FasL and LIGHT. In this study, we found that DcR3.Fc profoundly modulated dendritic cell differentiation and maturation from CD14(+) monocytes, including the up-regulation of CD86/B7.2, and the down-regulation of CD40, CD54/ICAM-1, CD80/B7.1, CD1a, and HLA-DR. Moreover, DcR3-treated dendritic cells suppressed CD4(+) T cell proliferation in an allogeneic MLR and up-regulated IL-4 secretion of CD4(+)CD45RA(+) T cells. This suggests that DcR3.Fc may act not only as a decoy receptor to FasL and LIGHT, but also as an effector molecule to skew T cell response to the Th2 phenotype.

引用

收藏

页码：4846 / 4853

页数：8

相关论文

共 39 条

[21] Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer [J].

Pitti, RM ;

Marsters, SA ;

Lawrence, DA ;

Roy, M ;

Kischkel, FC ;

Dowd, P ;

Huang, A ;

Donahue, CJ ;

Sherwood, SW ;

Baldwin, DT ;

Godowski, PJ ;

Wood, WI ;

Gurney, AL ;

Hillan, KJ ;

Cohen, RL ;

Goddard, AD ;

Botstein, D ;

Ashkenazi, A .

NATURE, 1998, 396 (6712) :699-703

[22] Distinct dendritic cell subsets differentially regulate the class of immune response in vivo [J].

Pulendran, B ;

Smith, JL ;

Caspary, G ;

Brasel, K ;

Pettit, D ;

Maraskovsky, E ;

Maliszewski, CR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1036-1041

[23] Reciprocal control of T helper cell and dendritic cell differentiation [J].

Rissoan, MC ;

Soumelis, V ;

Kadowaki, N ;

Grouard, G ;

Briere, F ;

Malefyt, RD ;

Liu, YJ .

SCIENCE, 1999, 283 (5405) :1183-1186

[24]

Roth W, 2001, CANCER RES, V61, P2759

[25]

Salomon B, 1998, J IMMUNOL, V161, P5138

[26] Osteoprotegerin: A novel secreted protein involved in the regulation of bone density [J].

Simonet, WS ;

Lacey, DL ;

Dunstan, CR ;

Kelley, M ;

Chang, MS ;

Luthy, R ;

Nguyen, HQ ;

Wooden, S ;

Bennett, L ;

Boone, T ;

Shimamoto, G ;

DeRose, M ;

Elliott, R ;

Colombero, A ;

Tan, HL ;

Trail, G ;

Sullivan, J ;

Davy, E ;

Bucay, N ;

RenshawGegg, L ;

Hughes, TM ;

Hill, D ;

Pattison, W ;

Campbell, P ;

Sander, S ;

Van, G ;

Tarpley, J ;

Derby, P ;

Lee, R ;

Boyle, WJ .

CELL, 1997, 89 (02) :309-319

[27] CROSS-LINKING OF OX40 LIGAND, A MEMBER OF THE TNF/NGF CYTOKINE FAMILY, INDUCES PROLIFERATION AND DIFFERENTIATION IN MURINE SPLENIC B-CELLS [J].

STUBER, E ;

NEURATH, M ;

CALDERHEAD, D ;

FELL, HF ;

STROBER, W .

IMMUNITY, 1995, 2 (05) :507-521

[28] The dual functions of Fas ligand in the regulation of peripheral CD8+ and CD4+ T cells [J].

Suzuki, I ;

Fink, PJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1707-1712

[29] Fas ligand costimulates the in vivo proliferation of CD8+ T cells [J].

Suzuki, I ;

Martin, S ;

Boursalian, TE ;

Beers, C ;

Fink, PJ .

JOURNAL OF IMMUNOLOGY, 2000, 165 (10) :5537-5543

[30] Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand [J].

Suzuki, I ;

Fink, PJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :123-128

← 1 2 3 4 →